


Product Name : Brevilin A
Cat. No. : PC-25382
CAS No. : 16503-32-5
Molecular Formula : C₂₀H₂₆O₅
Molecular Weight : 346.42
Target : STAT
Solubility : 10 mM in DMSO



Biological Activity

Brevilin A is an orally active STAT3/JAK inhibitor with IC₅₀ of 10.6 μM (STAT3), exerts potent anti-inflammatory, antitumor, immunosuppressive, and anti-liver fibrosis effects, also reduces protein levels of LRRC15 in RA fibroblast-like synoviocytes (RA-FLSs).

Brevilin A is reported to regulate the SIRT1/Nrf2/GPX4 signaling pathway to inhibit the production of MMP1 and MMP3 and alleviate joint damage in mice.

Brevilin A effectively alleviates LPS-induced lung damage, inflammatory infiltration, and the production of proinflammatory cytokines in LPS-induced acute lung injury.

Brevilin A significantly reduced the protein levels of LRRC15 in TNF-α-induced RA fibroblast-like synoviocytes (RA-FLSs).

Brevilin A significantly inhibited STAT3 phosphorylation without affecting total STAT3 protein levels

Brevilin A ameliorates arthritis symptoms in CIA rats.

References

Chen X, et al. PLoS One. 2013 May 21;8(5):e63697.

Qiao Z, et al. Arthritis Res Ther. 2025 Aug 20;27(1):167.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com